Barbara J. Farrell

1Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia 2Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia 3Bruyère Health Research Institute, Ottawa, Ontario, Canada 4Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada 5Health Evidence Synthesis Recommendations and Impact, School of Public Health, University of Adelaide, Adelaide, South...

Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. Supporting Information Filename Description bcpt_70235-sup-0001-Supplementary_Information.docxWord 2007 document , 6 MB Appendix A: Checklist for Reporting of Survey Studies (CROSS). Appendix B: Survey Questions. Appendix C: List of organisations based on published endorsement information.

COI conflict of interest ICOD International Conference on Deprescribing MedTech company medical technology company 1 Introduction and Background Deprescribing—the planned and supervised process of dose reduction or stopping of medications that may no longer be beneficial or may be causing harm [1]—has emerged as a crucial strategy to address the growing challenge of inappropriate polypharmacy [2, 3].